SCHEMBL5075007

SCHEMBL5075007

CCCCN(Cc1ccc(O)c(OCC)c1)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.44
C5AR1 P21730 1/20 0.40
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ATP4A P20648 3/20 0.36
ATP4B P51164 3/20 0.36
BCHE P06276 1/20 0.35
HDAC1 Q13547 1/20 0.35
CRHR1 P34998 2/20 0.35
LMNA P02545 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34
HTT P42858 1/20 0.34
DRD2 P14416 1/20 0.34
DRD1 P21728 1/20 0.34
DRD4 P21917 1/20 0.34
DRD5 P21918 1/20 0.34
DRD3 P35462 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5072402 0.96 MAPT (0.43) MAPTC5AR1MEN1KMT2AATP4A
SCHEMBL5136707 0.92 MAPT (0.42) MAPTC5AR1MEN1KMT2AATP4A
SCHEMBL648771 0.89 C5AR1 (0.45) C5AR1MEN1KMT2ABCHEHDAC1
SCHEMBL651447 0.88 C5AR1 (0.46) MAPTC5AR1ATP4AATP4BBCHE
SCHEMBL5135588 0.88 C5AR1 (0.45) C5AR1ATP4AATP4BBCHEHDAC1
SCHEMBL5134767 0.88 MAPT (0.40) MAPTC5AR1MEN1KMT2AGAA
SCHEMBL5137336 0.85 ATP4A (0.46) C5AR1ATP4AATP4BDRD2DRD3
SCHEMBL5072435 0.85 C5AR1 (0.46) MAPTC5AR1MEN1KMT2ABCHE
SCHEMBL649712 0.84 C5AR1 (0.49) C5AR1ATP4AATP4BBCHEHDAC1
SCHEMBL5070033 0.84 C5AR1 (0.41) C5AR1MEN1KMT2ACRHR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed